Amgen annual shareholders’ equity
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Amgen Shareholders’ Equity Growth & History (AMGN)
Amgen's shareholders’ equity was $8.66B for fiscal 2025.
View full Amgen company overviewAmgen annual shareholders’ equity history
| Fiscal year | Period ended | Shareholders’ equity | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $8.66B | $2.78B | +47.32% |
| 2024 | 2024-12-31 | $5.88B | −$355.0M | −5.70% |
| 2023 | 2023-12-31 | $6.23B | $2.57B | +70.23% |
| 2022 | 2022-12-31 | $3.66B | −$3.04B | −45.36% |
| 2021 | 2021-12-31 | $6.70B | −$2.71B | −28.79% |
| 2020 | 2020-12-31 | $9.41B | −$264.0M | −2.73% |
| 2019 | 2019-12-31 | $9.67B | −$2.83B | −22.62% |
| 2018 | 2018-12-31 | $12.50B | −$12.74B | −50.48% |
| 2017 | 2017-12-31 | $25.24B | −$4.63B | −15.51% |
| 2016 | 2016-12-31 | $29.88B | $1.79B | +6.38% |
| 2015 | 2015-12-31 | $28.08B | $2.31B | +8.94% |
| 2014 | 2014-12-31 | $25.78B | $3.68B | +16.66% |
| 2013 | 2013-12-31 | $22.10B | $3.04B | +15.93% |
| 2012 | 2012-12-31 | $19.06B | $31.0M | +0.16% |
| 2011 | 2011-12-31 | $19.03B | −$4.92B | −20.53% |
| 2010 | 2010-12-31 | $23.94B | $1.28B | +5.63% |
| 2009 | 2009-12-31 | $22.67B | $1.78B | +8.53% |
| 2008 | 2008-12-31 | $20.89B | $2.37B | +12.82% |
| 2007 | 2007-12-31 | $18.51B | — | — |
Amgen quarterly shareholders’ equity
Q4.08
Q2.09
Q3.09
Q4.09
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q4.11
Q4.12
Q1.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Shareholders’ equity | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $11.69B | $4.26B | +57.35% |
| Q1 2026 | 2026-03-31 | $9.19B | $2.98B | +48.06% |
| Q4 2025 | 2025-12-31 | $8.66B | $2.78B | +47.32% |
| Q3 2025 | 2025-09-30 | $9.62B | $2.09B | +27.79% |
| Q2 2025 | 2025-06-30 | $7.43B | $1.50B | +25.37% |
| Q1 2025 | 2025-03-31 | $6.21B | $1.19B | +23.60% |
| Q4 2024 | 2024-12-31 | $5.88B | −$355.0M | −5.70% |
| Q3 2024 | 2024-09-30 | $7.53B | −$129.0M | −1.68% |
| Q2 2024 | 2024-06-30 | $5.92B | −$856.0M | −12.62% |
| Q1 2024 | 2024-03-31 | $5.02B | −$326.0M | −6.10% |
| Q4 2023 | 2023-12-31 | $6.23B | $2.57B | +70.23% |
| Q3 2023 | 2023-09-30 | $7.66B | $4.00B | +109.58% |
| Q2 2023 | 2023-06-30 | $6.78B | $4.36B | +180.32% |
| Q1 2023 | 2023-03-31 | $5.35B | $4.43B | +483.84% |
| Q4 2022 | 2022-12-31 | $3.66B | −$3.04B | −45.36% |
| Q3 2022 | 2022-09-30 | $3.65B | −$4.56B | −55.54% |
| Q2 2022 | 2022-06-30 | $2.42B | — | — |
| Q1 2022 | 2022-03-31 | $916.0M | −$8.42B | −90.19% |
| Q4 2021 | 2021-12-31 | $6.70B | −$2.71B | −28.79% |
| Q3 2021 | 2021-09-30 | $8.22B | −$2.74B | −25.02% |
| Q1 2021 | 2021-03-31 | $9.33B | −$151.0M | −1.59% |
| Q4 2020 | 2020-12-31 | $9.41B | −$264.0M | −2.73% |
| Q3 2020 | 2020-09-30 | $10.96B | — | — |
| Q2 2020 | 2020-06-30 | $10.66B | −$135.0M | −1.25% |
| Q1 2020 | 2020-03-31 | $9.48B | −$1.35B | −12.44% |
| Q4 2019 | 2019-12-31 | $9.67B | −$2.83B | −22.62% |
| Q2 2019 | 2019-06-30 | $10.79B | −$4.12B | −27.60% |
| Q1 2019 | 2019-03-31 | $10.83B | −$4.79B | −30.65% |
| Q4 2018 | 2018-12-31 | $12.50B | −$12.74B | −50.48% |
| Q3 2018 | 2018-09-30 | $14.35B | −$17.88B | −55.48% |
| Q2 2018 | 2018-06-30 | $14.91B | −$16.81B | −53.00% |
| Q1 2018 | 2018-03-31 | $15.62B | −$15.02B | −49.02% |
| Q4 2017 | 2017-12-31 | $25.24B | −$4.63B | −15.51% |
| Q3 2017 | 2017-09-30 | $32.23B | $1.46B | +4.73% |
| Q2 2017 | 2017-06-30 | $31.72B | $1.59B | +5.27% |
| Q1 2017 | 2017-03-31 | $30.64B | $1.96B | +6.82% |
| Q4 2016 | 2016-12-31 | $29.88B | $1.79B | +6.38% |
| Q3 2016 | 2016-09-30 | $30.77B | $2.81B | +10.03% |
| Q2 2016 | 2016-06-30 | $30.13B | $2.65B | +9.64% |
| Q1 2016 | 2016-03-31 | $28.68B | $2.18B | +8.21% |
| Q4 2015 | 2015-12-31 | $28.08B | $2.31B | +8.94% |
| Q3 2015 | 2015-09-30 | $27.97B | $2.64B | +10.43% |
| Q2 2015 | 2015-06-30 | $27.48B | $3.10B | +12.72% |
| Q1 2015 | 2015-03-31 | $26.51B | $3.77B | +16.56% |
| Q4 2014 | 2014-12-31 | $25.78B | $3.68B | +16.66% |
| Q3 2014 | 2014-09-30 | $25.32B | $3.60B | +16.55% |
| Q2 2014 | 2014-06-30 | $24.38B | — | — |
| Q1 2014 | 2014-03-31 | $22.74B | $3.25B | +16.67% |
| Q4 2013 | 2013-12-31 | $22.10B | $3.04B | +15.93% |
| Q3 2013 | 2013-09-30 | $21.73B | — | — |
| Q1 2013 | 2013-03-31 | $19.49B | — | — |
| Q4 2012 | 2012-12-31 | $19.06B | $31.0M | +0.16% |
| Q4 2011 | 2011-12-31 | $19.03B | −$4.92B | −20.53% |
| Q1 2011 | 2011-03-31 | $24.98B | $2.65B | +11.84% |
| Q4 2010 | 2010-12-31 | $23.94B | $1.28B | +5.63% |
| Q3 2010 | 2010-09-30 | $24.07B | $1.21B | +5.31% |
| Q2 2010 | 2010-06-30 | $23.17B | $1.81B | +8.47% |
| Q1 2010 | 2010-03-31 | $22.34B | — | — |
| Q4 2009 | 2009-12-31 | $22.67B | $1.78B | +8.53% |
| Q3 2009 | 2009-09-30 | $22.86B | — | — |
| Q2 2009 | 2009-06-30 | $21.36B | — | — |
| Q4 2008 | 2008-12-31 | $20.89B | — | — |
Amgen shareholders’ equity trends
Over the last five fiscal years, Amgen's shareholders’ equity decreased from $9.41B to $8.66B, a change of −$751.0M. The latest reported quarter, Q2 2026, shows $11.69B.
About the metric
What shareholders’ equity means
Shareholders’ equity is the residual accounting value attributable to shareholders after liabilities are subtracted from assets. It can change through earnings, losses, dividends, share issuance, repurchases, and other comprehensive income.
Calculation and source
SEC-reported shareholders’ equity
TickerStat standardizes stockholders’ or shareholders’ equity reported in company SEC filings at each balance-sheet date. Negative equity is retained because it can be economically meaningful. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Amgen source filings ↗Community posts
Amgen–AstraZeneca combination cuts lung-cancer mortality risk by 58%
Amgen ($AMGN) disclosed detailed Phase 3 results showing that adding Imdelltra to AstraZeneca ($AZN)’s Imfinzi reduced the risk of death by 58% in first-line maintenance treatment of extensive-stage small-cell lung cancer. Median overall su ...
